Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Optimal Labeling For Opsumit Allows Actelion To Drop Promotion Of Tracleer

This article was originally published in The Pink Sheet Daily

Executive Summary

With a ‘clean’ label that differentiates macitentan from current standard of care, Actelion’s got what it wanted from FDA: a newly approved next-generation drug with a long patent life that can expand its presence in the pulmonary arterial hypertension market, and, importantly, protect its core franchise from upcoming generic competition.

Advertisement

Related Content

Opsumit Label And Pricing Suggest Actelion’s Gamble Ready To Pay Off
Europe’s CHMP Clears Just Two Drugs: Brintellix And Opsumit
Actelion Braces For Tracleer Patent Cliff With New Drugs, New Data Standards

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074923

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel